Search

Search results

1500 results found

Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study. Journal of inherited metabolic disease, 44(1), 253–263. https://doi.org/10.1002/jimd.12313

Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD). Journal of inherited metabolic disease, 42(1), 169–177.

Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia. 2022 Oct 20;13:846126. doi: 10.3389/fneur.2022.846126. eCollection 2022. PMID: 36341088

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. 2022 Dec;21(12):1099-1109. doi: 10.. PMID: 36402160

Parkinson Study Group NILO-PD Investigators and Collaborators (including Hauser RA). Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 2021;78:312-320.

Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America. NPJ Parkinsons Dis 2021;7:34. doi: 10.1038/s41531-021-00177-8.PMID: 33846349